{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:29:49Z","timestamp":1793690989742,"version":"4.5.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,19]]},"DOI":"10.7759\/cureus.19736","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T04:48:52Z","timestamp":1637297332000},"source":"Crossref","is-referenced-by-count":1,"title":["Atezolizumab-Induced Hypothyroidism in a Patient With Pre-existing Triiodothyronine (T3) Thyrotoxicosis Due to Graves\u2019 Disease: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Samson O","family":"Oyibo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed O","family":"Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2014.5.6.3","article-title":"Immune checkpoint blockade: a new paradigm in treating advanced cancer","volume":"5","author":"Kreamer KM","year":"2014","unstructured":"Kreamer KM. Immune checkpoint blockade: a new paradigm in treating advanced cancer. J Adv Pract Oncol. 2014, 5:418-31. 10.6004\/jadpro.2014.5.6.3","journal-title":"J Adv Pract Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll DM","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012, 12:252-64. 10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei SC","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018, 8:1069-86. 10.1158\/2159-8290.CD-18-0367","journal-title":"Cancer Discov"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally RK","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020, 12:738. 10.3390\/cancers12030738","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management","volume":"124","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer. 2018, 124:1111-21. 10.1002\/cncr.31200","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra M","year":"2018","unstructured":"Girotra M, Hansen A, Farooki A, et al.. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2018, 2:pky021. 10.1093\/jncics\/pky021","journal-title":"JNCI Cancer Spectr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley R","year":"2021","unstructured":"Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: a review. Clin Med (Lond). 2021, 21:e212-22. 10.7861\/clinmed.2020-0827","journal-title":"Clin Med (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer PC","year":"2018","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG, et al.. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018, 28:1243-51. 10.1089\/thy.2018.0116","journal-title":"Thyroid"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention\u00a0strategy","volume":"31","author":"Haanen J","year":"2020","unstructured":"Haanen J, Ernstoff MS, Wang Y, et al.. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention\u00a0strategy. Ann Oncol. 2020, 31:724-44. 10.1016\/j.annonc.2020.03.285","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S188893","article-title":"Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis","volume":"13","author":"Tie Y","year":"2019","unstructured":"Tie Y, Yang H, Zhao R, Zheng H, Yang D, Zhao J, Liu M. Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis. Drug Des Devel Ther. 2019, 13:523-38. 10.2147\/DDDT.S188893","journal-title":"Drug Des Devel Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal A","year":"2020","unstructured":"Kotwal A, Kottschade L, Ryder M. PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid. 2020, 30:177-84. 10.1089\/thy.2019.0250","journal-title":"Thyroid"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross DS","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, et al.. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016, 26:1343-421. 10.1089\/thy.2016.0229","journal-title":"Thyroid"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5897\/JDE11.004","article-title":"Syndrome of isolated FT3 toxicosis: a pilot study","volume":"3","author":"Kazanavicius G","year":"2012","unstructured":"Kazanavicius G, Lasaite L, Graziene A. Syndrome of isolated FT3 toxicosis: a pilot study. J Diabetes Endocrinol. 2012, 3:1-5. 10.5897\/JDE11.004","journal-title":"J Diabetes Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2019-cptn-10","article-title":"Immunotherapy in patients with autoimmune disease","volume":"12","author":"Rakshit S","year":"2020","unstructured":"Rakshit S, Molina JR. Immunotherapy in patients with autoimmune disease. J Thorac Dis. 2020, 12:7032-8. 10.21037\/jtd-2019-cptn-10","journal-title":"J Thorac Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/lmt-2021-0003","article-title":"Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data","volume":"8","author":"Calvo V","year":"2021","unstructured":"Calvo V, Fernandez MA, Collazo-Lorduy A, Franco F, Nurez B, Provencio M. Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. Lung Cancer Manag. 2021, 8:LMT18. 10.2217\/lmt-2021-0003","journal-title":"Lung Cancer Manag"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0639","article-title":"Immune-related thyroid dysfunction in patients with existing thyroid dysfunction","volume":"8","author":"Kaleta F","year":"2020","unstructured":"Kaleta F, Brody H, Namireddy P. Immune-related thyroid dysfunction in patients with existing thyroid dysfunction. J Immunother Cancer. 2020, 8:1-559. 10.1136\/jitc-2020-SITC2020.0639","journal-title":"J Immunother Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00442","article-title":"Rapid development of Graves\u2019 ophthalmopathy after treatment with ipilmumab and recurrence with pembrolizumab in a patient with previously treated Graves\u2019 disease","volume":"14","author":"Rhea L","year":"2018","unstructured":"Rhea L, Yoon JW, Jang S. Rapid development of Graves\u2019 ophthalmopathy after treatment with ipilmumab and recurrence with pembrolizumab in a patient with previously treated Graves\u2019 disease. J Oncol Pract. 2018, 14:747-9. 10.1200\/JOP.18.00442","journal-title":"J Oncol Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081944","article-title":"Graves' disease during immune checkpoint inhibitor therapy (a case series and literature review)","volume":"13","author":"Peiffert M","year":"2021","unstructured":"Peiffert M, Cugnet-Anceau C, Dalle S, et al.. Graves' disease during immune checkpoint inhibitor therapy (a case series and literature review). Cancers (Basel). 2021, 13:1944. 10.3390\/cancers13081944","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.07.023","article-title":"Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced\/metastatic urinary tract carcinoma","volume":"138","author":"Loriot Y","year":"2020","unstructured":"Loriot Y, Sternberg CN, Castellano D, et al.. Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced\/metastatic urinary tract carcinoma. Eur J Cancer. 2020, 138:202-11. 10.1016\/j.ejca.2020.07.023","journal-title":"Eur J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/78056-atezolizumab-induced-hypothyroidism-in-a-patient-with-pre-existing-triiodothyronine-t3-thyrotoxicosis-due-to-graves-disease-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:05:48Z","timestamp":1793689548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/78056-atezolizumab-induced-hypothyroidism-in-a-patient-with-pre-existing-triiodothyronine-t3-thyrotoxicosis-due-to-graves-disease-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.19736","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,19]]}}}